Tolvaptan success in rare kidney disease
This article was originally published in Scrip
Otsuka’s vasopressin V2 receptor antagonist tolvaptan has met the primary endpoint in a Phase III trial in patients with autosomal dominant polycystic kidney disease (ADPKD), providing a strong basis for global regulatory filings in this additional indication, the company says.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.